	US 12,410,184 B2
	Crystalline forms of a menin inhibitor
Roger Paul Bakale, San Diego, CA (US); Craig Michael Bowe, San Diego, CA (US); Dipanjan Sengupta, San Diego, CA (US); Patricia Andres, Bend, OR (US); and Xiaohu Deng, San Diego, CA (US)
Assigned to Kura Oncology, Inc., San Diego, CA (US)
Filed by Kura Oncology, Inc., San Diego, CA (US)
Filed on Sep. 6, 2024, as Appl. No. 18/827,512.
Application 18/827,512 is a continuation of application No. PCT/US2024/038216, filed on Jul. 16, 2024.
Claims priority of provisional application 63/655,384, filed on Jun. 3, 2024.
Claims priority of provisional application 63/514,089, filed on Jul. 17, 2023.
Prior Publication US 2025/0101035 A1, Mar. 27, 2025
Int. Cl. C07D 495/04 (2006.01)

CPC C07D 495/04 (2013.01)

35 Claims

1. A crystalline Form 1 of of (S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile having an X-ray powder diffraction (XRPD) pattern with at least three characteristic peaks selected from 4.1° 2-Theta, 5.4° 2-Theta, 6.6° 2-Theta, 8.2° 2-Theta, 9.5° 2-Theta, 12.3° 2-Theta, 13.1° 2-Theta, 13.9° 2-Theta, 15.9° 2-Theta, 16.4° 2-Theta, 17.0° 2-Theta, 17.5° 2-Theta, 19.7° 2-Theta, and 22.6° 2-Theta.